Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2024

Supporting Information for:

Copper-Catalyzed Asymmetric 1,2-Arylboration of Enamines: Access to Borate-Containing 3,3'-Disubstituted Isoindolinones

Jia-Qi Xie,^a Bing-Xia Wang,^a Ren-Xiao Liang^{*,a}, and Yi-Xia Jia^{*a,b}

^aCollege of Chemical Engineering, State Key Laboratory Breeding Base of Green-Chemical Synthesis Technology, Zhejiang University of Technology, Chaowang Road 18[#], Hangzhou 310014, China ^bSchool of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin 300384, China.

E-mail: liangrx@zjut.edu.cn, yxjia@zjut.edu.cn

Table of Contents

1. General information	S1
2. Chromatographic conditions for GC analyses	S1
3. Table S1 Time-controlling experiments	S1
4. Synthesis of enamine substrates	S2
5. General procedure for the Cu-catalyzed enantioselective arylboration reaction	S17
6. Scale-up experiment and synthetic transformations	S48
7. Crystal report	S54
8. References	S57
9. Copies of NMR spectra	S58

1. General information

Unless otherwise noted, all reactions were carried out under N2 atmosphere in sealed tube with magnetic stirring. All reagents were purchased from commercial suppliers with the highest purity grade, and used directly without further purification. ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were recorded on Bruker AVANCE III 400 MHz, 500 MHz, or 600 MHz using CDCl₃ as solvent with TMS as internal standard. Melting points were measured on a Büchi Melting Point B-545 apparatus and uncorrected. HRMS were recorded on Thermo Scientific LTQ Orbitrap XL or Agilent 6210 TOF LC/MS mass spectrometer. GC analyses were performed using Agilent 7820A Gas Chromatograph System. Optical rotations were determined using a Rudolph Autopol IV polarimeter. HPLC analyses were performed using Agilent 1260 chromatography. Chiralpak AD-H, OD-H, OJ-H and AS-H columns were purchased from Daicel Chemical Industries, LTD. Cellulose-1, Cellulose-2 and Amylose-2 columns were purchased from Phenomenex. Solvents were purified prior to use according to conventional procedures. Reactions were monitored by thin layer chromatography (TLC) using silica gel plates. For reactions that require heating, a heating mantle was used as the heat source. Column chromatography was carried out using silica gel (200-300 mesh).

2. Chromatographic conditions for GC analyses

Each sample was analyzed by Agilent 7820A Gas Chromatograph System. The operational conditions were as follows: air flow rate of 400 mL/min; hydrogen flow rate of 30 mL/min; nitrogen flow rate of 25 mL/min; injector temperature at 300 °C; split ratio of 7.6923:1, split flow rate of 50 mL/min; injection volume of 1 μ L; column oven temperature initially held at 50 °C for 2 min, raised from 50 °C to 300 °C at the rate of 20 °C/min and maintained for 2 min. The retention time of the benzophenone was 6.787 min; the retention time of **1a** was 9.106 min; the retention time of **2a** was 9.644 min.

3. Table S1 Time-controlling experiments



Entry	t	Conv. (%)	Yield (%)	Ee (%)
1	6	86	64(52)	95
2	8	90	77	95
3	10	95	89(83)	95
4	12	97	73	95
5	16	98	69	95
6	24	99	43(29)	95

4. Synthesis of enamine substrates

4.1 General procedure for the preparation of enamine 1a-1w and 1z^[1]:



Synthesis of S2:

To a 100 mL oven-dried flask equipped with a stir bar was added 2-iodobenzoic acid **S1** (1.0 equiv.) and solvent DCM (0.5 M) with 2 drops of DMF. Then the flask was stirred at an ice-water bath. Oxalyl chloride (1.5 equiv.) was slowly added to the solution. The mixture was allowed to warm to room temperature and stirred overnight. After the reaction was completed, the solvent was removed under reduced pressure. The obtained product **S2** was used for the next step without further purification.

Synthesis of S4:

To a 100 mL oven-dried flask equipped with a stir bar was charged with CH_3NH_2 (8 M in EtOH, 4.0 equiv.), ketone **S3** (1.0 equiv.), and KOH (50 mg/mmol) and stirred overnight at room temperature. After the reaction was completed, the mixture was extracted with DCM (3 times) and the combined organic phases were dried over anhydrous Na₂SO₄. Solid were filtered and the filtrate were concentrated under reduced pressure to give **S4**.

Synthesis of **1a-1w** and **1z**:

To a 100 mL oven-dried flask was charged with S4, NEt₃ (1.5 equiv.), and anhydrous DCM. The flask was put in an ice-water bath and stirred at 0 °C. Then S2 (1.2 equiv.) was added into the mixture slowly. The resulting mixture was allowed to warm to room temperature and stirred overnight. After the reaction was completed, the mixture was extracted with DCM (3 times) and the combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate/petroleum ether to give compounds **1a-1w** and **1z**.

4.2 General procedure for preparation of enamine 1x:



To a 100 mL oven-dried flask equipped with a stir bar was charged with anhydrous DCM, 0.4 mL acetone, CH_3NH_2 (8.0 M in EtOH, 4.0 equiv.), and 4Å MS (2.5 g) activated with a heat gun for half an hour under nitrogen atmosphere. The resulting mixture was stirred at room temperature. After 6 hours, Et_3N (5.5 mmol, 1.1 equiv.) was added to the system. Then 2-iodobenzoyl chloride was slowly added under an ice-water bath, and the reaction was stirred at room temperature for another 2 hours. After the reaction was completed, the solvent was removed under reduced pressure to obtain the crude product, which was purified by column chromatography to yield the substrates **1x** (PE/EA v/v = 10:1).

4.3 General procedure for the preparation of enamine $1y^{[2]}$:



Synthesis of **S6**^[3]:

N-vinyl formamide (5.0 mmol, 1.0 equiv.), Et_3N (6.0 mmol, 1.2 equiv.), DMAP (5.0 mol%, 30.1 mg) and anhydrous THF (30 mL) were added to a three-necked round-

bottomed flask equipped with an addition funnel under nitrogen balloon. The mixture was cooled to 0 $^{\circ}$ C in an ice-water bath. Freshly distilled 2-iodobenzoyl chloride (5.75 mmol, 1.15 equiv.) was added into the addition funnel and slowly added into the reaction mixture at a rate keeping the temperature below 5 $^{\circ}$ C over 1 h. After the droping was finished, the reaction was allowed to stir for additional 16 hours. A solution of 5 N NaOH (15 mmol/3 mL H₂O) was then slowly added at 0-5 $^{\circ}$ C over 2 hours. Then the mixture was extracted with EA (3 times) and the combined organic phases were washed with saturated NaCl aqueous solution, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure using rotary evaporation to give the crude product, which was purified by flash chromatography on silica gel with petroleum ether/ethyl acetate (PE: EA= 10:1 - 3:1) to give a white solid **S6**. The solid was further dried in a vacuum oven.

Synthesis of **1y**:

To a 100 mL oven-dried flask equipped with a stirring bar was charged with **S6** and anhydrous THF under nitrogen atmosphere. The flask was put in an ice-water bath and stirred at 0 °C. Then NaH (1.1 equiv.) was added into the mixture slowly and the resulting mixture was allowed to warm to room temperature and stirred for 1 hour. The mixture was cooled to 0 °C in an ice-water bath again and MeI (1.5 equiv.) was added dropwise. After stirring at room temperature for 2 hours, the reaction mixture was quenched with water. The solution was extracted with DCM (3 times) and the combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate/petroleum ether to give compound **1y** (PE: EA = 20:1).

Characterization data of compounds 1a-1z:

2-Iodo-N-methyl-N-(1-phenylvinyl)benzamide (1a):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 110-111 °C; 40% yield, 8.3:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.86 (d, *J* = 8.4 Hz, 0.11H), 7.71 (d, *J* = 8.4 Hz, 0.90H), 7.58-7.57 (m, 0.27H), 7.46-7.42 (m, 0.27H), 7.30

(s, 4.48H), 7.17-7.09 (m, 0.32H), 7.03-7.01 (m, 0.88H), 6.96-6.95 (m, 0.90H), 6.89-6.86 (m, 0.89H), 5.79 (s, 0.11H), 5.54 (s, 0.11H), 5.31 (s, 0.89H), 5.30 (s, 0.89H), 3.35 (s, 2.68H), 2.98 (s, 0.33H). ¹³C NMR (150 MHz, CDCl₃): δ 170.5, 148.0, 142.2, 139.1, 136.4, 130.2, 129.7, 128.7, 128.6, 128.5, 127.2, 127.0, 126.7, 125.8, 112.7, 112.3, 94.3, 38.8, 36.3. HRMS *m*/*z* (ESI+): Calculated for C₁₆H₁₅INO⁺ ([M+H]⁺): 364.0193, found 364.0188.

2-Bromo-N-methyl-N-(1-phenylvinyl)benzamide (1a'):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 94-95 °C; 52% yield, 9.1:1 ratio of isomers (for the last step); ¹H NMR (400 MHz, CDCl₃): δ 7.45-7.37 (m, 1.60H), 7.34-7.28 (m, 4.34H), 7.08-7.00 (m, 2.61H), 5.80 (s, 0.10H), 5.49 (s, 0.10H), 5.31 (s, 0.90H), 5.27 (s, 0.90H), 3.34 (s, 2.70H), 3.01 (s, 0.30H). ¹³C NMR (100 MHz, CDCl₃): δ 169.3, 147.9, 138.4, 136.2, 132.9, 132.6, 130.4, 129.8, 128.8, 128.6, 127.1, 126.6, 125.8, 120.3, 112.7, 112.0, 36.0. HRMS (ESI+) m/z: calculated for C₁₆H₁₅BrNO⁺[M+H]⁺: 316.0332, found 316.0329.

2-Iodo-4-methoxy-N-methyl-N-(1-phenylvinyl)benzamide (1b):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow oil; 40% yield, 11.5:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.54-7.41 (m, 0.31H), 7.36-7.29 (m, 4.89H), 7.23 (s, 0.92H), 6.95 (s, 0.07H), 6.88 (d, *J* = 8.4 Hz, 0.90H), 6.54 (d, *J* = 8.4 Hz, 0.91H), 5.76 (s, 0.08H), 5.49 (s, 0.08H), 5.30 (s, 0.92H), 5.22 (s, 0.92H), 3.79 (s, 0.24H), 3.67 (s, 2.76H), 3.32 (s, 2.76H), 2.99 (s, 0.24H). ¹³C NMR (150 MHz, CDCl₃): δ 170.6, 159.4, 148.3, 136.5, 134.5, 128.64, 128.55, 127.5, 125.7, 124.5, 113.0, 112.0, 94.7, 55.3, 36.4. HRMS *m*/*z* (ESI+): Calculated for C₁₇H₁₇INO₂⁺ ([M+H]⁺): 394.0298, found 394.0293.



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 85-87 °C; 43% yield, 7.7:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.73-7.68 (m, 0.17H), 7.56 (s, 0.88H), 7.42-7.37 (m, 0.58H), 7.31 (s, 4.45H), 7.24 (s, 0.17H), 6.87-6.82 (m, 1.75H), 5.78 (s, 0.12H), 5.52 (s, 0.12H), 5.31 (s, 0.88H), 5.27 (s, 0.88H), 3.32 (s, 2.65H), 2.98 (s, 0.35H), 2.34 (s, 0.35H), 2.19 (s, 2.65H). ¹³C NMR (150 MHz, CDCl₃): δ 170.8, 148.1, 140.0, 139.7, 139.4, 136.4, 128.7, 128.6, 128.0, 126.4, 125.9, 112.3, 94.3, 36.2, 20.6. HRMS *m*/*z* (ESI+): Calculated for C₁₇H₁₇INO⁺ ([M+H]⁺): 378.0349, found 378.0346.

4-Chloro-2-iodo-N-methyl-N-(1-phenylvinyl)benzamide (1d):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 105-106 °C; 38% yield, 10.0:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.87-7.84 (m, 0.09H), 7.70 (d, *J* = 1.8 Hz, 0.91H), 7.56-7.54 (m, 0.18H), 7.44-7.34 (m, 0.46H), 7.32-7.29 (m, 2.72H), 7.28-7.27 (m, 1.82H), 7.00-6.98 (m, 0.92H), 6.87-6.85 (m, 0.91H), 5.78 (s, 0.09H), 5.51 (s, 0.09H), 5.33 (s, 0.91H), 5.28 (s, 0.91H), 3.35 (s, 2.73H), 2.98 (s, 0.28H). ¹³C NMR (150 MHz, CDCl₃): δ 169.5, 147.8, 140.6, 138.4, 136.2, 134.4, 128.8, 128.6, 127.7, 127.3, 127.2, 125.6, 112.6, 112.3, 94.3, 92.2, 38.7, 36.3. HRMS *m/z* (ESI+): Calculated for C₁₆H₁₄ClINO⁺ ([M+H]⁺): 397.9803, found 397.9799.

4-Fluoro-2-iodo-N-methyl-N-(1-phenylvinyl)benzamide (1e):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 132-133 °C; 33% yield, 10.0:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.66-7.55 (m, 0.54H), 7.43 (d, J = 8.4 Hz, 0.91H), 7.32-7.26 (m, 4.54H), 7.18-7.04 (m, 0.18H), 6.92-6.90 (m, 0.91H), 6.75-6.72 (m, 0.91H), 5.79 (s, 0.09H), 5.52 (s, 0.09H), 5.33 (s, 0.91H), 5.28 (s, 0.91H), 3.37 (s, 2.72H), 2.99 (s, 0.27H). ¹³C NMR (150 MHz, CDCl₃): δ 169.9, 161.4 (d, J = 252.0 Hz), 148.3, 138.5, 136.6, 128.9, 128.7, 128.0 (d, J = 9.0 Hz), 126.3 (d, J = 22.5 Hz), 125.7, 114.5 (d, J = 21.0 Hz), 112.3, 94.0, 38.9, 36.6. ¹⁹F NMR (377 MHz, CDCl₃): δ -110.1, -110.8. HRMS m/z (ESI+): Calculated for C₁₆H₁₄FINO⁺ ([M+H]⁺): 382.0099, found 382.0093.

2-Iodo-N-methyl-N-(1-phenylvinyl)-4-(trifluoromethyl)benzamide (1f):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); yellow oil; 37% yield, 11.1:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 8.11 (d, *J* = 6.0 Hz, 0.08H), 7.94 (d, *J* = 6.0 Hz, 0.90H), 7.71-7.69 (m, 0.08H), 7.57-7.55 (m, 0.17H), 7.50-7.48 (m, 0.08H), 7.39-7.36 (m, 0.25H), 7.29-7.26 (m, 5.46H), 7.04-7.02 (m, 0.92H), 5.80 (s, 0.08H), 5.54 (s, 0.08H), 5.33 (s, 0.92H), 5.31 (s, 0.92H), 3.36 (s, 2.75H), 2.97 (s, 0.25H). ¹³C NMR (150 MHz, CDCl₃): δ 169.3, 169.2, 147.7, 146.6, 146.0, 145.7, 136.1, 136.0 (t, *J* = 3.0 Hz), 135.8 (q, *J* = 4.5 Hz), 131.3 (q, *J* = 33.0 Hz), 129.0, 128.7, 128.5, 128.4, 127.3, 126.7, 125.8, 125.7, 124.1 (q, *J* = 4.5 Hz), 122.3 (q, *J* = 271.5 Hz), 112.8, 112.5, 93.9, 91.9, 38.6, 36.3. ¹⁹F NMR (377 MHz, CDCl₃): δ -62.9, -63.0. HRMS *m*/*z* (ESI+): Calculated for C₁₇H₁₄F₃INO⁺ ([M+H]⁺): 432.0067, found 432.0062.

2-Iodo-5-methoxy-N-methyl-N-(1-phenylvinyl)benzamide (1g):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid, Mp = 71-72 °C; 42% yield, 9.1:1 ratio of

atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.71 (d, *J* = 8.4 Hz, 0.10H), 7.58-7.56 (m, 0.23H), 7.54 (d, *J* = 9.0 Hz, 0.90H), 7.40-7.37 (m, 0.27H), 7.33-7.29 (m, 4.50H), 6.91 (s, 0.10H), 6.71-6.66 (m, 0.10H), 6.48-6.44 (m, 1.79H), 5.79 (s, 0.10H), 5.55 (s, 0.10H), 5.36 (s, 0.90H), 5.35 (s, 0.90H), 3.83 (s, 0.30H), 3.41 (s, 2.70H), 3.37 (s, 2.70H), 3.00 (s, 0.30H). ¹³C NMR (150 MHz, CDCl₃): δ 170.4, 158.8, 148.0, 143.0, 140.1, 139.9, 139.7, 136.8, 128.7, 128.6, 125.9, 125.8, 117.1, 116.6, 113.2, 112.7, 112.5, 112.1, 82.6, 80.4, 55.5, 55.0, 38.8, 36.5. HRMS *m*/*z* (ESI+): Calculated for C₁₇H₁₇INO₂⁺ ([M+H]⁺): 394.0298, found 394.0294.

2-Iodo-N,5-dimethyl-N-(1-phenylvinyl)benzamide (1h):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 65-67 °C; 42% yield, 6.7:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.71 (d, *J* = 7.8 Hz, 0.13H), 7.58-7.57 (m, 0.26H), 7.54-7.53 (m, 0.87H), 7.40-7.34 (m, 0.39H), 7.30-7.27 (m, 2.61H), 7.25-7.23 (m, 1.73H), 7.17 (s, 0.13H), 6.92 (d, *J* = 7.8 Hz, 0.13H), 6.68-6.67 (m, 1.74H), 5.79 (s, 0.13H), 5.54 (s, 0.13H), 5.33 (s, 0.87H), 5.29 (s, 0.87H), 3.37 (s, 2.60H), 3.00 (s, 0.39H), 2.35 (s, 0.39H), 1.98 (s, 2.61H). ¹³C NMR (150 MHz, CDCl₃): δ 170.7, 148.2, 142.1, 139.0, 138.7, 137.2, 137.0, 131.3, 130.6, 128.6, 128.5, 127.9, 125.8, 112.7, 112.1, 89.9, 87.9, 38.8, 36.5, 20.9, 20.5. HRMS *m*/*z* (ESI+): Calculated for C₁₇H₁₇INO⁺ ([M+H]⁺): 378.0349, found 378.0344.

5-Bromo-2-iodo-N-methyl-N-(1-phenylvinyl)benzamide (1i):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 107-108 °C; 41% yield, 8.3:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.70 (d, *J* = 8.4 Hz, 0.11H), 7.55-7.54 (m, 0.32H), 7.51-7.50 (m, 0.89H), 7.40-7.34 (m, 0.43H), 7.31-7.30 (m, 2.67H), 7.23-7.21 (m, 1.78H), 6.98-6.97 (m, 1.77H), 5.79 (s, 0.11H), 5.53 (s, 0.11H),

5.33 (s, 0.89H), 5.32 (s, 0.89H), 3.39 (s, 2.67H), 3.00 (s, 0.33H). ¹³C NMR (150 MHz, CDCl₃): δ 168.9, 148.1, 146.7, 143.9, 140.7, 140.3, 136.7, 135.1, 133.4, 132.7, 130.1, 129.9, 128.9, 128.7, 128.6, 125.8, 125.7, 122.9, 121.5, 112.8, 112.2, 92.0, 90.1, 38.7, 36.7. HRMS *m*/*z* (ESI+): Calculated for C₁₆H₁₄BrINO⁺ ([M+H]⁺): 441.9298, found 441.9293.

5-Chloro-2-iodo-N-methyl-N-(1-phenylvinyl)benzamide (1j):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 80-82 °C; 34% yield, 6.3:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.79 (d, *J* = 8.4 Hz, 0.14H), 7.60 (d, *J* = 8.4 Hz, 0.86H), 7.42-7.36 (m, 0.96H), 7.33-7.25 (m, 5.17H), 7.12-7.10 (m, 0.13H), 6.87-6.85 (m, 1.72H), 5.82 (s, 0.14H), 5.55 (s, 0.14H), 5.35 (s, 0.86H), 5.34 (s, 0.86H), 3.40 (s, 2.57H), 3.02 (s, 0.41H). ¹³C NMR (150 MHz, CDCl₃): δ 169.0, 148.0, 143.6, 140.4, 140.1, 136.6, 135.1, 135.0, 133.6, 130.4, 129.8, 128.9, 128.6, 127.1, 125.8, 125.7, 112.8, 112.2, 91.2, 38.7, 36.6. HRMS *m*/*z* (ESI+): Calculated for C₁₆H₁₄ClINO⁺ ([M+H]⁺): 397.9803, found 397.9800.

5-Fluoro-2-iodo-N-methyl-N-(1-phenylvinyl)benzamide (1k):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 87-88 °C; 32% yield, 9.1:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.83-7.80 (m, 0.10H), 7.65-7.63 (m, 0.90H), 7.56-7.55 (m,0.19H), 7.41-7.36 (m, 0.30H), 7.33-7.26 (m, 4.50H), 7.15-7.09 (m, 0.10H), 6.89-6.88 (m, 0.10H), 6.67-6.63 (m, 1.80H), 5.80 (s, 0.10H), 5.54 (s, 0.10H), 5.34 (s, 0.90H), 5.32 (s, 0.90H), 3.37 (s, 2.70H), 3.00 (s, 0.30H). ¹³C NMR (150 MHz, CDCl₃): δ 169.2, 161.9 (d, *J* = 247.5 Hz), 148.0, 144.0 (d, *J* = 6.0 Hz), 140.6 (d, *J* = 7.5 Hz), 136.4, 129.0, 128.9, 128.8, 128.7, 125.9, 125.8, 117.3 (d, *J* = 22.5 Hz), 114.5 (d, *J* = 24.0 Hz), 112.9, 112.4, 87.3, 38.8, 36.5. ¹⁹F NMR (377 MHz, CDCl₃): δ -

112.4, -114.0. HRMS m/z (ESI+): Calculated for C₁₆H₁₄FINO⁺ ([M+H]⁺): 382.0099, found 382.0093.

2-Iodo-4,5-dimethoxy-N-methyl-N-(1-phenylvinyl)benzamide (11):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow oil, 36% yield (for the last step); ¹H NMR (500 MHz, CDCl₃): δ 7.28 (s, 5H), 7.07 (s, 1H), 6.33 (s, 1H), 5.35 (s, 1H), 5.32 (s, 1H), 3.78 (s, 3H), 3.38 (s, 3H), 3.34 (s, 3H). ¹³C NMR (150 MHz, CDCl₃): δ 170.3, 149.0, 148.0, 147.9, 136.9, 134.5, 128.5, 128.4, 125.4, 121.0, 112.2, 110.1, 82.4, 55.9, 55.1, 36.6. HRMS *m*/*z* (ESI+): Calculated for C₁₈H₁₉INO₃⁺ ([M+H]⁺): 424.0404, found 424.0400.

4,5-Difluoro-2-iodo-N-methyl-N-(1-phenylvinyl)benzamide (1m):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 75-76 °C; 38% yield, 14.3:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.66-7.63 (m, 0.07H), 7.54-7.52 (m, 0.13H), 7.49-7.46 (m, 0.93H), 7.44-7.37 (m, 0.26H), 7.34-7.30 (m, 2.79H), 7.26-7.24 (m, 1.86H), 6.75-6.72 (m, 0.93H), 5.79 (s, 0.07H), 5.52 (s, 0.07H), 5.36 (s, 0.93H), 5.31 (s, 0.93H), 3.38 (s, 2.79H), 3.00 (s, 0.20H). ¹³C NMR (150 MHz, CDCl₃): δ 168.4, 150.2 (dd, *J* = 13.5 Hz, 6.0 Hz), 148.5 (dd, *J* = 13.5 Hz, 3.0 Hz), 147.9, 138.9 (t, *J* = 4.5 Hz), 136.4, 135.0, 132.1, 128.9, 128.7, 128.3 (d, *J* = 4.5 Hz), 127.8 (d, *J* = 19.5 Hz), 112.7, 112.2, 86.3, 36.6, 33.8. ¹⁹F NMR (377 MHz, CDCl₃): δ -133.8 (d, *J* = 22.62 Hz), -134.5 (d, *J* = 18.85 Hz), -135.8 (d, *J* = 18.85 Hz), -137.5 (d, *J* = 18.85 Hz). HRMS *m*/*z* (ESI+): Calculated for C₁₆H₁₃F₂INO⁺ ([M+H]⁺): 400.0004, found 400.0001.



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid, Mp = 80-81 °C; 40% yield, 10.0:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.87 (d, *J* = 7.8 Hz, 0.09H), 7.73 (d, *J* = 7.8 Hz, 0.91H), 7.52-7.35 (m, 0.63H), 7.26-7.24 (m, 1.81H), 7.06-7.04 (m, 0.91H), 6.99-6.97 (m, 0.91H), 6.91-6.84 (m, 2.75H), 5.69 (s, 0.09H), 5.43 (s, 0.09H), 5.198 (s, 0.91H), 5.195 (s, 0.91H), 3.82 (s, 2.73H), 3.33 (s, 2.73H), 2.98 (s, 0.27H), 1.71 (s, 0.27H). ¹³C NMR (150 MHz, CDCl₃): δ 170.6, 160.1, 147.6, 142.4, 139.2, 129.7, 128.8, 127.21, 127.18, 126.5, 114.0, 110.6, 94.4, 55.3, 36.1. HRMS *m/z* (ESI+): Calculated for C₁₇H₁₇INO₂⁺ ([M+H]⁺): 394.0298, found 394.0295.

2-Iodo-N-methyl-N-(1-(p-tolyl)vinyl)benzamide (10):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 137-139 °C; 40% yield, 9.1:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.85 (d, *J* = 8.4 Hz, 0.10H), 7.71 (d, *J* = 7.8 Hz, 0.89H), 7.47-7.34 (m, 0.70H), 7.22-7.21 (m, 1.81H), 7.13-7.12 (m, 1.80H), 7.04-6.98 (m, 1.81H), 6.89-6.86 (m, 0.90H), 5.74 (s, 0.10H), 5.48 (s, 0.10H), 5.27 (s, 0.90H), 5.23 (s, 0.90H), 3.31 (s, 2.70H), 2.97 (s, 0.29H), 2.34 (s, 3.00H). ¹³C NMR (150 MHz, CDCl₃): δ 170.5, 147.8, 142.3, 139.1, 138.8, 133.3, 130.1, 129.6, 129.3, 128.4, 127.2, 127.0, 126.5, 125.9, 125.7, 111.7, 111.5, 94.3, 38.8, 36.0, 21.1. HRMS *m*/*z* (ESI+): Calculated for C₁₇H₁₇INO⁺ ([M+H]⁺): 378.0349, found 378.0346.

N-(1-(4-ethylphenyl)vinyl)-2-iodo-N-methylbenzamide (1p):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 104-106 °C; 39% yield, 8.3:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.86 (d, *J* = 7.8 Hz, 0.11H), 7.72 (d, *J* = 7.8 Hz, 0.88H), 7.50-7.35 (m, 0.54H), 7.24-7.23 (m, 1.79H), 7.16-7.14 (m, 1.78H), 7.11-7.09 (m, 0.21H), 7.04-6.98 (m, 1.78H), 6.89-6.87 (m, 0.89H), 5.76 (s, 0.11H), 5.49 (s, 0.11H), 5.27 (s, 0.89H), 5.23 (s, 0.89H), 3.32 (s, 2.68H), 2.98 (s, 0.32H), 2.64 (q, *J* = 7.8 Hz, 2.00H), 1.23 (t, *J* = 7.8 Hz, 3.00H). ¹³C NMR (150 MHz, CDCl₃): δ 170.6, 147.9, 145.2, 142.3, 139.2, 133.6, 130.2, 129.7, 128.5, 128.1, 127.2, 126.6, 125.9, 111.8, 111.5, 94.4, 38.9, 36.1, 28.5, 15.4. HRMS *m*/*z* (ESI+): Calculated for C₁₈H₁₉INO⁺ ([M+H]⁺): 392.0506, found 392.0500.

N-(1-(4-fluorophenyl)vinyl)-2-iodo-N-methylbenzamide (1q):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 116-117 °C; 54% yield, 7.1:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.87 (d, *J* = 7.8 Hz, 0.13H), 7.71 (d, *J* = 7.8 Hz, 0.87H), 7.57-7.56 (m, 0.25H), 7.45-7.44 (m, 0.24H), 7.35-7.33 (m, 0.25H), 7.27-7.23 (m, 1.75H), 7.06-7.04 (m, 0.90H), 7.00-6.97 (m, 1.76H), 6.94-6.88 (m, 1.74H), 6.84-6.82 (m, 0.12H), 5.72 (s, 0.12H), 5.51 (s, 0.12H), 5.29 (s, 0.88H), 5.24 (s, 0.88H), 3.36 (s, 2.63H), 2.99 (s, 0.37H). ¹³C NMR (150 MHz, CDCl₃): δ 170.5, 162.8 (d, *J* = 247.5 Hz), 147.3, 142.3, 142.1, 139.22, 139.15, 132.9 (d, *J* = 3.0 Hz), 129.8, 129.7, 127.6 (d, *J* = 7.5 Hz), 127.2, 127.0, 126.7, 126.5, 115.6 (d, *J* = 22.5 Hz), 114.5, 112.1, 110.4, 94.3, 94.1, 36.4, 36.1. ¹⁹F NMR (377 MHz, CDCl₃): δ -112.3, -112.9. HRMS *m*/*z* (ESI+): Calculated for C₁₆H₁₄FINO⁺ ([M+H]⁺): 382.0099, found 382.0093.

2-Iodo-N-(1-(3-methoxyphenyl)vinyl)-N-methylbenzamide (1r):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid, Mp = 98-99 °C; 37% yield, 7.1:1 ratio of

atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.87 (d, *J* = 8.4 Hz, 0.12H), 7.72 (d, *J* = 7.8 Hz, 0.88H), 7.45-7.43 (m, 0.12H), 7.36-7.29 (m, 0.36H), 7.24-7.21 (m, 0.89H), 7.17-7.10 (m, 0.36H), 7.06-7.04 (m, 0.88H), 6.99-6.97 (m, 0.88H), 6.90-6.83 (m, 2.63H), 6.80-6.79 (m, 0.88H), 5.79 (s, 0.12H), 5.54 (s, 0.12H), 5.30 (s, 0.88H), 5.29 (s, 0.88H), 3.83 (s, 0.36H), 3.78 (s, 2.64H), 3.35 (s, 2.64H), 2.99 (s, 0.36H). ¹³C NMR (150 MHz, CDCl₃): δ 170.6, 159.8, 148.0, 142.2, 139.2, 138.0, 130.2, 129.72, 129.66, 128.5, 127.2, 127.0, 126.8, 118.4, 114.1, 112.9, 112.5, 111.7, 94.3, 55.3, 38.9, 36.3. HRMS *m*/*z* (ESI+): Calculated for C₁₇H₁₇INO₂⁺ ([M+H]⁺): 394.0298, found 394.0294.

2-Iodo-N-methyl-N-(1-(m-tolyl)vinyl)benzamide (1s):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 104-106 °C; 38% yield, 8.3:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.88-7.86 (m, 0.11H), 7.70 (d, *J* = 10.2 Hz, 0.89H), 7.45-7.26 (m, 0.75H), 7.20-7.17 (m, 0.89H), 7.11-7.02 (m, 3.57H), 6.98-6.97 (m, 0.89H), 6.89-6.86 (m, 0.89H), 5.78 (s, 0.11H), 5.51 (s, 0.11H), 5.29 (s, 0.89H), 5.27 (s, 0.89H), 3.35 (s, 2.67H), 2.98 (s, 0.32H), 2.38 (s, 0.32H), 2.33 (s, 2.67H). ¹³C NMR (150 MHz, CDCl₃): δ 170.6, 148.2, 142.2, 139.2, 138.3, 136.4, 130.2, 129.7, 129.6, 128.5, 127.2, 126.7, 126.5, 123.0, 112.5, 112.0, 94.3, 38.9, 36.4, 21.4. HRMS *m/z* (ESI+): Calculated for C₁₇H₁₇INO⁺ ([M+H]⁺): 378.0349, found 378.0345.

N-(1-(3,5-dimethylphenyl)vinyl)-2-iodo-*N*-methylbenzamide (1t):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 107-108 °C; 44% yield, 10.0:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.86 (d, *J* = 7.8 Hz, 0.09H), 7.70 (d, *J* = 7.8 Hz, 0.91H), 7.46-7.35 (m, 0.18H), 7.20 (s, 0.18H), 7.13-

7.08 (m, 0.18H), 7.06-7.03 (m, 0.92H), 7.00-6.98 (m, 0.92H), 6.93-6.86 (m, 3.65H), 5.75 (s, 0.09H), 5.48 (s, 0.09H), 5.26 (s, 0.91H), 5.23 (s, 0.91H), 3.35 (s, 2.73H), 2.98 (s, 0.27H), 2.34 (s, 0.54H), 2.28 (s, 5.46H). ¹³C NMR (150 MHz, CDCl₃): δ 170.5, 148.3, 142.2, 139.1, 138.1, 136.4, 130.5, 130.2, 129.6, 128.4, 127.1, 126.7, 123.7, 123.5, 111.7, 112.2, 94.3, 38.9, 36.3, 21.2. HRMS m/z (ESI+): Calculated for C₁₈H₁₉INO⁺ ([M+H]⁺): 392.0506, found 392.0499.

N-(1-(benzo[d][1,3]dioxol-5-yl)vinyl)-2-iodo-N-methylbenzamide (1u):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid, Mp = 101-102 °C; 45% yield, 6.3:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.86 (d, *J* = 8.4 Hz, 0.14H), 7.72 (d, *J* = 8.4 Hz, 0.86H), 7.44-7.43 (m, 0.14H), 7.34-7.33 (m, 0.14H), 7.11-7.05 (m, 1.41H), 7.00-6.99 (m, 0.86H), 6.91-6.88 (m, 0.86H), 6.81-6.73 (m, 2.60H), 5.96 (s, 2.00H), 5.66 (s, 0.14H), 5.43 (s, 0.14H), 5.19 (s, 0.86H), 5.17 (s, 0.86H), 3.32 (s, 2.58H), 2.97 (s, 0.42H). ¹³C NMR (150 MHz, CDCl₃): δ 170.6, 148.2, 148.0, 147.7, 142.2, 139.2, 130.8, 129.8, 128.5, 127.2, 126.6, 120.0, 111.0, 108.3, 106.4, 106.2, 101.4, 101.3, 94.3, 38.9, 36.3. HRMS m/z (ESI+): Calculated for C₁₇H₁₅INO₃⁺ ([M+H]⁺): 408.0091, found 408.0086.

2-Iodo-N-methyl-N-(1-(naphthalen-2-yl)vinyl)benzamide (1v):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 116-118 °C; 34% yield, 9.1:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 8.06-8.04 (m, 0.10H), 7.89-7.68 (m, 4.89H), 7.53-7.45 (m, 2.22H), 7.42-7.37 (m, 0.90H), 7.16-7.10 (m, 0.16H), 7.00-6.98 (m, 0.93H), 6.94-6.91 (m, 0.90H), 6.84-6.81 (m, 0.90H), 5.93 (s, 0.10H), 5.63 (s, 0.10H), 5.47 (s, 0.90H), 5.42 (s, 0.90H), 3.42 (s, 2.69H), 3.04 (s, 0.30H). ¹³C NMR (150 MHz, CDCl₃): δ 170.7, 148.0, 142.2, 139.3, 139.2, 133.5, 133.3, 133.0, 130.3,

129.8, 128.5, 128.3, 127.5, 127.2, 126.7, 126.60, 126.55, 126.3, 125.1, 123.7, 123.4, 113.2, 113.0, 94.3, 39.0, 36.4. HRMS m/z (ESI+): Calculated for C₂₀H₁₇INO⁺([M+H]⁺): 414.0349, found 414.0342.

2-Iodo-N-methyl-N-(1-(thiophen-3-yl)vinyl)benzamide (1w):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 134-136 °C; 44% yield, 7.1:1 ratio of atropisomers (for the last step); ¹H NMR (600 MHz, CDCl₃): δ 7.88-7.86 (m, 0.12H), 7.74 (d, *J* = 24.6 Hz, 0.88H), 7.47-7.41 (m, 0.26H), 7.35-7.26 (m, 2.21H), 7.09-7.07 (m, 1.02H), 7.02-7.00 (m, 1.66H), 6.93-6.90 (m, 0.87H), 5.74 (s, 0.12H), 5.45 (s, 0.12H), 5.28 (s, 0.88H), 5.26 (s, 0.88H), 3.36 (s, 2.63H), 3.03 (s, 0.37H). ¹³C NMR (150 MHz, CDCl₃): δ 170.4, 143.7, 142.2, 139.2, 138.8, 130.3, 129.8, 128.5, 127.2, 126.7, 126.6, 126.4, 125.4, 122.7, 112.1, 94.2, 36.0. HRMS m/z (ESI+): Calculated for C₁₄H₁₃INOS⁺ ([M+H]⁺): 369.9757, found 369.9754.

2-Iodo-N-methyl-N-(prop-1-en-2-yl)benzamide (1x):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 106-107 °C; 34% yield, 3.3:1 ratio of atropisomers (for the last step); ¹H NMR (500 MHz, CDCl₃): δ 7.80 (d, *J* = 8.0 Hz, 1.00H), 7.38-7.30 (m, 0.99H), 7.18-7.01 (m, 1.99H), 4.93 (s, 1.24H), 4.74 (s, 0.75H), 3.22 (s, 2.30H), 2.97 (s, 0.69H), 2.13 (s, 0.73H), 1.82 (s, 2.30H). ¹³C NMR (125 MHz, CDCl₃): δ 169.4, 144.5, 142.7, 139.1, 129.7, 127.3, 127.0, 113.8, 93.6, 33.7, 20.5. HRMS m/z (ESI+): Calculated for C₁₁H₁₂INNaO⁺ ([M+Na]⁺): 323.9856, found 323.9848.



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:20 (v/v); yellow oil; 87% yield, 3.0:1 ratio of atropisomers (for the last step); ¹H NMR (500 MHz, CDCl₃): δ 7.84 (dd, *J* = 8.0 Hz, 1.0 Hz, 0.97H), 7.70-7.65 (m, 0.24H), 7.43-7.39 (m, 1.00H), 7.24-7.21 (m, 0.99H), 7.12-7.09 (m, 0.99H), 6.41 (dd, *J* = 15.5 Hz, 9.0 Hz, 0.74H), 4.63 (dd, *J* = 6.5 Hz, 1.0 Hz, 0.25H), 4.60 (s, 0.25H), 4.54 (dd, *J* = 15.5 Hz, 1.5 Hz, 0.75H), 4.27 (dd, *J* = 9.0 Hz, 1.0 Hz, 0.75H), 3.27 (s, 2.25H), 2.93 (s, 0.75H). ¹³C NMR (125 MHz, CDCl₃): δ 169.8, 169.2, 142.1, 141.5, 139.3, 139.2, 134.6, 132.1, 130.6, 130.5, 128.4, 128.3, 127.7, 127.2, 95.8, 94.3, 92.6, 92.1, 33.1, 28.6. HRMS m/z (ESI+): Calculated for C₁₀H₁₁INO⁺ ([M+H]⁺): 287.9880, found 287.9884.

2-Iodo-N-methyl-N-(1-phenylprop-1-en-1-yl)benzamide (1z):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:10 (v/v); white solid, Mp = 75-76 °C; 51% yield, 5.0:1 ratio of isomers (for the last step); ¹H NMR (500 MHz, CDCl₃): δ 7.85 (dd, *J* = 8.0 Hz, 1.5 Hz, 0.16H), 7.70 (dd, *J* = 8.0 Hz, 1.5 Hz, 0.82H), 7.51-7.39 (m, 0.83H), 7.30-7.22 (m, 2.84H), 7.07-7.01 (m, 2.60H), 6.90-6.83 (m, 1.70H), 6.11 (q, *J* = 7.5 Hz, 0.16H), 5.92 (q, *J* = 7.5 Hz, 0.84H), 3.38 (s, 2.51H), 2.86 (s, 0.49H), 1.91 (d, *J* = 7.0 Hz, 0.50H), 1.63 (d, *J* = 7.5 Hz, 2.52H). ¹³C NMR (125 MHz, CDCl₃): δ 170.7, 142.9, 141.0, 139.2, 139.0, 136.1, 135.3, 130.0, 129.4, 129.1, 128.4, 128.3, 128.2, 127.9, 127.8, 127.2, 127.1, 127.0, 125.1, 124.6, 94.0, 92.1, 38.5, 37.2, 14.2. HRMS (ESI+) m/z: calculated for C₁₇H₁₆INNaO⁺ ([M+Na]⁺): 400.0169, found 400.0196.

5. General procedure for the Cu-catalyzed enantioselective arylboration reaction



General procedure for the Cu-catalyzed enantioselective arylboration reaction of 1a-Iw: In an N₂-filled glovebox, to an oven-dried Schlenk tube equipped with a stir bar was charged with CuI (10 mol%), (*R*)-xyl-BINAP (12 mol%), and KO'Bu (0.3 mmol, 1.5 equiv.). The tube was sealed with cap and removed from the glovebox. Toluene (2.0 mL) was then introduced via syringe. The mixture was stirred at 40 °C for 1 h. Then B_2pin_2 (0.3 mmol, 1.5 equiv.) and **1a-1w** were added into the mixture and warmed to 40 °C. The reaction was stirred at 40 °C for 6-48 h. When the reaction was completed, the mixture was extracted with EA. The combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluenting with petroleum ether/EtOAc to afford the products **2**.

(*R*)-2-Methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2a):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow solid; Mp = 108-110 °C; 83% yield; $[\alpha]_D^{26} = -58.25$ (*c* 0.5, CH₂Cl₂), 95% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; t_{minor} = 17.77 min, t_{major} = 20.81 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.87-7.85 (m, 1H), 7.46-7.43 (m, 1H), 7.42-7.39 (m, 1H), 7.33-7.27 (m, 3H), 7.25-7.21 (m, 3H), 2.88 (s, 3H), 2.17 (d, *J* = 18.0 Hz, 1H), 1.96 (d, *J* = 17.4 Hz, 1H), 0.97 (d, *J* = 17.4 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.5, 151.2, 141.4, 131.6, 131.5, 128.7, 127.8, 127.6, 126.0, 123.1, 122.2, 83.2, 68.4, 24.9,

24.5, 24.4. HRMS *m*/*z* (ESI+): Calculated for C₂₂H₂₇BNO₃⁺([M+H]⁺): 364.2079, found 364.2077.



(*R*)-5-Methoxy-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2b):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:3 (v/v); white solid; Mp = 138-139 °C; 57% yield; $[\alpha]_D^{23} = -57.65$ (*c* 0.5, CH₂Cl₂), 92% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; t_{minor} = 26.91 min, t_{major} = 34.19 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, *J* = 8.4 Hz, 1H), 7.32-7.24 (m, 3H), 7.23-7.19 (m, 2H), 6.92-6.90 (m, 1H), 6.69 (d, *J* = 2.0 Hz, 1H), 3.77 (s, 3H), 2.83 (s, 3H), 2.11 (d, *J* = 14.8 Hz, 1H), 1.89 (d, *J* = 14.8 Hz, 1H), 0.99 (d, *J* = 9.6 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.2, 162.7, 153.4, 141.5, 128.7, 127.6, 126.0, 124.4, 124.3, 114.4, 107.1, 83.2, 68.1, 55.5, 24.8, 24.52, 24.51. HRMS *m/z* (ESI+): Calculated for C₂₃H₂₉BNO₄⁺ ([M+H]⁺): 394.2184, found 394.2182.



Signal 1: DAD1 A, Sig=254,4 Ref=360,100



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	26.905	BB	0.9028	2237.57568	35.23751	3.9922
2	34.189	BB	1.2778	5.38118e4	608.45349	96.0078

(*R*)-2,5-dimethyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2c):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow oil; 61% yield; $[\alpha]_D^{23} = -81.30$ (*c* 0.5, CH₂Cl₂), 95% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; t_{minor} = 17.74 min, t_{major} = 20.56 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.70 (d, *J* = 7.8 Hz, 1H), 7.30-7.27 (m, 2H), 7.25-7.22 (m, 1H), 7.20-7.17 (m, 3H), 6.983-6.980 (m, 1H), 2.83 (s, 3H), 2.32 (s, 3H), 2.11 (d, *J* = 14.4 Hz, 1H), 1.89 (d, *J* = 14.4 Hz, 1H), 0.95 (d, *J* = 22.8 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.6, 151.5, 142.0, 141.6, 129.0, 128.8, 128.6, 127.5, 126.0, 122.9, 122.6, 83.2, 68.2, 24.8, 24.49, 24.45, 21.9. HRMS *m*/*z* (ESI+): Calculated for C₂₃H₂₉BNO₃⁺ ([M+H]⁺): 378.2235, found 378.2233.



Peak RetTime Type Width Height Area Area % [min] [min] [mAU*s] [mAU] # 0.4910 7401.96045 217.54048 17.484 BV 49.9857 1 0.7007 7406.18311 2 20.309 VB 151.93304 50.0143 mAU 20.557 800 600 · 400 -17.738 200 0 14 16 18 20 22 24 12 28 10 26 Signal 1: DAD1 A, Sig=254,4 Ref=360,100 Peak RetTime Type Width Height Area Area % [mAU*s] # [min] [min] [mAU] ----| 0.4573 17.738 BB 801.56012 25.18791 2.3677 1

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

2

20.557 BB

(*R*)-5-Chloro-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2d):

0.7438 3.30519e4

645.03485

97.6323



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 112-113 °C; 42% yield; $[\alpha]_D^{20} = -64.70$ (*c* 0.5, CH₂Cl₂), 87% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 230 nm; t_{minor} = 15.32 min, t_{major} = 17.89 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.75 (d, *J* = 8.4 Hz, 1H), 7.37-7.35 (m, 1H), 7.32-7.29 (m, 2H), 7.27-7.26 (m, 1H), 7.19-7.16 (m, 3H), 2.83 (s, 3H), 2.12 (d, *J* = 15.0 Hz, 1H), 1.89 (d, *J* = 14.4 Hz, 1H), 0.99 (d, *J* = 10.8 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃): δ 167.4, 152.8, 140.6, 137.7, 130.1, 128.9, 128.4, 127.9, 126.0, 124.3, 122.8, 83.4, 68.2,

24.9, 24.53, 24.49. HRMS m/z (ESI+): Calculated for C₂₂H₂₆BClNO₃⁺ ([M+H]⁺): 398.1689, found 398.1690.



(*R*)-5-Fluoro-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2e):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 127-129 °C; 64% yield; $[α]_D^{23} = -76.15$ (*c* 0.5, CH₂Cl₂), 91% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; t_{minor} = 13.86 min, t_{major} = 16.93 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.82-7.80 (m, 1H), 7.32-7.26 (m, 3H), 7.19-7.17 (m, 2H), 7.09-7.06 (m, 1H), 6.90-6.88 (m, 1H), 2.84 (s, 3H), 2.11 (d, *J* = 15.0 Hz, 1H), 1.91 (d, *J* = 14.4 Hz, 1H), 0.99 (d, *J* = 12.0 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 167.4, 165.1 (d, *J* = 249.0 Hz), 153.7 (d, *J* = 9.0 Hz), 140.8, 128.8, 127.9, 127.6 (d, *J* = 3.0 Hz), 125.9, 125.0 (d, *J* = 10.5 Hz), 115.6 (d, *J* = 22.5 Hz), 109.7 (d, *J* = 24.0 Hz), 83.3, 68.2, 25.0, 24.52, 24.50. ¹⁹F NMR (377 MHz, CDCl₃): δ -107.4. HRMS *m*/z (ESI+): Calculated for C₂₂H₂₆BFNO₃⁺ ([M+H]⁺): 382.1984, found 382.1981.





Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	13.861	BB	0.4998	6013.04883	175.48909	50.3907
2	16.947	BB	0.5037	5919.80664	172.77185	49.6093
mAU 700						
600 -						



S23

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	13.863	MM	0.5784	411.18347	11.84742	4.5210
2	16.934	BB	0.5058	8683.87207	250.88623	95.4790

(*R*)-2-Methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-5-(t-rifluoromethyl)isoindolin-1-one (2f):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow oil; 36% yield; $[\alpha]_D^{20} = -55.20$ (*c* 0.5, CH₂Cl₂), 82% ee [Phenomenex Lux 5u Amylose-2 column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 98/02, 0.7 mL/min, 230 nm; t_{minor} = 19.33 min, t_{major} = 22.18 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.95 (d, *J* = 7.8 Hz, 1H), 7.68-7.67 (m, 1H), 7.50 (s, 1H), 7.33-7.27 (m, 3H), 7.19-7.17 (m, 2H), 2.85 (s, 3H), 2.19 (d, *J* = 15.0 Hz, 1H), 1.89 (d, *J* = 15.0 Hz, 1H), 0.96 (d, *J* = 10.2 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 167.0, 151.7, 140.1, 135.0, 133.4 (q, *J* = 33.0 Hz), 128.9, 128.1, 126.0, 125.2 (q, *J* = 3.0 Hz), 123.8 (q, *J* = 271.5 Hz), 123.6, 119.7 (q, *J* = 4.5 Hz), 83.4, 68.7, 24.9, 24.48, 24.46. ¹⁹F NMR (377 MHz, CDCl₃): δ -62.3. HRMS *m*/*z* (ESI+): Calculated for C₂₃H₂₆BF₃NO₃⁺ ([M+H]⁺): 432.1952, found 432.1950.



Signal 4: DAD1 D, Sig=230,4 Ref=360,100



Signal 4: DAD1 D, Sig=230,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	19.334	BB	0.4837	374.25452	9.25721	9.0368
2	22.179	BB	0.7345	3767.17725	69.27238	90.9632

(*R*)-6-Methoxy-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2g):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:3 (v/v); white solid; Mp = 118-120 °C; 90% yield; $[\alpha]_D^{20} = -103.35$ (*c* 0.5, CH₂Cl₂), 95% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 90/10, 0.7 mL/min, 210 nm; t_{minor} = 12.98 min, t_{major} = 17.06 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.35 (d, *J* = 2.4 Hz, 1H), 7.30-7.27 (m, 2H), 7.25-7.22 (m, 1H), 7.20-7.18 (m, 2H), 7.12-7.10 (m, 1H), 7.00-6.99 (m, 1H), 3.85 (s, 3H), 2.86 (s, 3H), 2.13 (d, *J* = 15.0 Hz, 1H), 1.91 (d, *J* = 15.0 Hz, 1H), 0.98 (d, *J* = 13.8 Hz, 12H).

¹³C NMR (150 MHz, CDCl₃): δ 168.3, 159.8, 143.7, 141.6, 132.9, 128.6, 127.5, 125.9, 123.1, 119.7, 105.9, 83.2, 68.0, 55.7, 25.0, 24.50, 24.45. HRMS *m/z* (ESI+): Calculated for C₂₃H₂₉BNO₄⁺ ([M+H]⁺): 394.2184, found 394.2185.



Signal 2: DAD1 B, Sig=210,4 Ref=360,100



Signal 2: DAD1 B, Sig=210,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	12.979	BB	0.3945	1607.48083	58.15455	2.6592
2	17.063	BB	0.6089	5.88428e4	1398.38684	97.3408

(R)-2,6-diMethyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2h):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 98-100 °C; 78% yield; $[\alpha]_D^{20} = -95.50 (c \ 0.5, CH_2Cl_2)$, 93% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 90/10, 0.7 mL/min, 254 nm; t_{minor} = 12.44 min, t_{major} = 14.03 min]; ¹H NMR (400 MHz, CDCl_3): δ 7.65-7.64 (m, 1H), 7.30-7.23 (m, 4H), 7.20-7.18 (m, 2H), 7.10-7.08 (m, 1H), 2.85 (s, 3H), 2.40 (s, 3H), 2.13 (d, *J* = 14.4 Hz, 1H), 1.90 (d, *J* = 14.8 Hz, 1H), 0.96 (d, *J* = 13.2 Hz, 12H). ¹³C NMR (150 MHz, CDCl_3): δ 168.5, 148.6, 141.6, 137.7, 132.5, 131.6, 128.6, 127.5, 125.9, 123.2, 121.9, 83.1, 68.2, 24.8, 24.5, 24.4, 21.2. HRMS *m*/*z* (ESI+): Calculated for C₂₃H₂₉BNO₃⁺ ([M+H]⁺): 378.2235, found 378.2232.



Signal 1: DAD1 A, Sig=254,4 Ref=360,100



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	12.443	BB	0.3680	268.59204	10.51500	3.3700
2	14.025	BB	0.4938	7701.48975	225.88440	96.6300

(*R*)-6-Bromo-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2i):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 109-110 °C; 59% yield; $[\alpha]_D^{20} = -93.85$ (*c* 0.5, CH₂Cl₂), 94% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 90/10, 0.7 mL/min, 280 nm; t_{minor} = 12.74 min, t_{major} = 20.01 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.98 (d, *J* = 1.8 Hz, 1H), 7.55-7.53 (m, 1H), 7.32-7.29 (m, 2H), 7.27 (s, 1H), 7.18-7.17 (m, 2H), 7.10-7.08 (m, 1H), 2.85 (s, 3H), 2.12 (d, *J* = 15.0 Hz, 1H), 1.92 (d, *J* = 15.0 Hz, 1H), 0.99 (d, *J* = 10.8 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 166.9, 150.0, 140.6, 134.4, 133.6, 128.8, 127.8, 126.1, 125.9, 123.9, 121.8, 83.3, 68.3, 25.0, 24.47, 24.46. HRMS *m/z* (ESI+): Calculated for C₂₂H₂₆BBrNO₃⁺ ([M+H]⁺): 442.1184, found 442.1181.



Signal 7: DAD1 G, Sig=280,4 Ref=360,100



Signal 7: DAD1 G, Sig=280,4 Ref=360,100

576
424

(R)-6-Chloro-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2j):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 97-99 °C; 66% yield; $[\alpha]_D^{20} = -$ 84.60 (c 0.5, CH₂Cl₂), 90% ee [Daicel Chiralcel AD-H column (25 cm \times 0.46 cm ID), n-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 260 nm; $t_{minor} = 11.99 min$, $t_{major} = 18.68 min$]; ¹H NMR (600 MHz, CDCl₃): δ 7.80 (d, J = 1.8 Hz, 1H), 7.38-7.36 (m, 1H), 7.30-7.27 (m, 2H), 7.25-7.23 (m, 1H), 7.17-7.12 (m, 3H), 2.83 (s, 3H), 2.11 (d, *J* = 15.0 Hz, 1H), 1.91 (d, J = 15.0 Hz, 1H), 0.98 (d, J = 10.8 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 167.0, 149.5, 140.7, 134.0, 133.4, 131.6, 128.8, 127.8, 125.9, 123.6, 123.1, 83.3, 68.3, 25.0, 24.49, 24.47. HRMS m/z (ESI+): Calculated for C₂₂H₂₆BClNO₃⁺ ([M+H]⁺): 398.1689, found 398.1687.



Signal 5: DAD1 E, Sig=260,4 Ref=360,100



(*R*)-6-Fluoro-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2k):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 124-126 °C; 60% yield; $[\alpha]_D^{20} = -$ 87.60 (c 0.5, CH₂Cl₂), 92% ee [Daicel Chiralcel AD-H column (25 cm \times 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; $t_{minor} = 16.83$ min, $t_{major} = 21.56$ min]; ¹H NMR (600 MHz, CDCl₃): δ 7.51-7.49 (m, 1H), 7.31-7.28 (m, 2H), 7.24-7.23 (m, 1H), 7.18-7.15 (m, 3H), 7.13-7.09 (m, 1H), 2.84 (s, 3H), 2.12 (d, J = 15.0 Hz, 1H), 1.92 (d, J = 15.0 Hz, 1H), 0.97 (d, J = 10.8 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 167.3, 162.7 (d, J = 244.5 Hz), 146.8 (d, J = 1.5 Hz), 141.0, 133.7 (d, J = 7.5 Hz), 128.8, 127.8, 125.9, 123.9 (d, J = 7.5 Hz), 118.9 (d, J = 22.5 Hz), 109.7 (d, J = 22.5 Hz), 83.3, 68.2, 25.1, 24.6, 24.5. ¹⁹F NMR (377 MHz, CDCl₃): δ -113.8. HRMS *m/z* (ESI+): Calculated for C₂₂H₂₆BFNO₃⁺ ([M+H]⁺): 382.1984, found 382.1982.





Signal 1: DAD1 A, Sig=254,4 Ref=360,100



Peak RetTime Type Height Width Area Area % # [min] [min] [mAU*s] [mAU] 16.827 BB 0.4156 530.65662 18.55925 3.8634 1 21.559 BB 0.7772 1.32049e4 2 244.08205 96.1366

(*R*)-5,6-diMethoxy-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)methyl)isoindolin-1-one (2l):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:3 (v/v); white solid; Mp = 138-140 °C; 87% yield; $[\alpha]_D^{23} = -59.10$ (*c* 0.5, CH₂Cl₂), 95% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 90/10, 0.7 mL/min, 230 nm; t_{major} = 11.73 min, t_{minor} = 14.66 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.30-7.27 (m, 2H), 7.26 (s, 1H), 7.24-7.23 (m, 1H), 7.17-7.15 (m, 2H), 6.68 (s, 1H), 3.92 (s, 3H), 3.81 (s, 3H), 2.80 (s, 3H), 2.08 (d, *J* = 15.0 Hz, 1H), 1.85 (d, *J* = 14.4 Hz, 1H), 0.98 (d, *J* = 9.6 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.4, 152.5, 149.5, 144.9, 141.4, 128.6, 127.5, 126.0, 123.9, 104.64, 104.56, 83.1, 67.9, 56.2, 56.1, 24.8, 24.5, 24.4. HRMS *m*/*z* (ESI+): Calculated for C₂₄H₃₁BNO₅⁺ ([M+H]⁺): 424.2290, found 424.2287.



Signal 4: DAD1 D, Sig=230,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	11.733	BB	0.3859	5231.38135	194.44115	49.6589
2	14.649	BB	0.4948	5303.25586	152.85544	50.3411



(*R*)-5,6-diFluoro-2-methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2m):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow oil; 23% yield; $[\alpha]_D^{25} = -57.98$ (*c* 0.5, CH₂Cl₂), 80% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 280 nm; t_{minor} = 12.37 min, t_{major} = 14.70 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.65-7.61 (m, 1H), 7.35-7.32 (m, 1H), 7.31-7.28 (m, 2H), 7.18-7.15 (m, 2H), 7.05-7.01 (m, 1H), 2.84 (s, 3H), 2.11 (d, *J* = 14.8 Hz, 1H), 1.91 (d, *J* = 14.8 Hz, 1H), 1.02 (d, *J* = 4.8 Hz, 12H). ¹³C NMR (125 MHz, CDCl₃): δ 166.6, 154.0 (d, *J* = 13.75 Hz), 151.9 (dd, *J* = 23.75 Hz, 13.75 Hz), 149.8 (d, *J* = 13.75 Hz), 147.6 (dd, *J* = 7.5 Hz, 3.75 Hz), 140.3, 128.9, 128.0, 127.8 (dd, *J* = 7.5 Hz, 2.5 Hz), 125.8, 111.7 (t, *J* = 17.5 Hz), 83.4, 68.2, 25.1, 24.51, 24.48. ¹⁹F NMR (377 MHz, CDCl₃): δ -130.7 (d, *J* = 18.85 Hz), -137.0 (d, *J* = 22.62 Hz). HRMS *m*/*z* (ESI+): Calculated for C₂₂H₂₅BF₂NO₃⁺ ([M+H]⁺): 400.1890, found 400.1890.



Signal 7: DAD1 G, Sig=280,4 Ref=360,100

Peak	RetTime Type	Width	Area	Height	Area
#	[min]	[min]	[mAU*s]	[mAU]	%
1	12.838 BB	0.4336	489.07779	16.13838	50.5583
2	15.392 BB	0.5133	478.27713	13.24425	49.4417
mAU					
80					
40			.703		
20	.365		14		
0	12	1			
-20 -20 -20 -20 -20 -20 -20 -20 -20 -20	12 1	3 14	15	16	17 min
Sign	al 7: DAD1 G.	Sig=280.	4 Ref=360.1	00	
0			,_		
Peak	RetTime Type	Width	Area	Height	Area
#	[min]	[min]	[mAU*s]	[mAU]	%
1	12.365 BB	0.3724	93.97633	3.55544	9.6885
2	14.703 BB	0.4975	875.99823	25.97378	90.3115

(*R*)-3-(4-Methoxyphenyl)-2-methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2n):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:3 (v/v); yellow oil; 50% yield; $[\alpha]_D^{20} = -65.50$ (*c* 0.5, CH₂Cl₂),

94% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 210 nm; t_{minor} = 24.04 min, t_{major} = 27.81 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.84-7.81 (m, 1H), 7.44-7.36 (m, 2H), 7.20-7.18 (m, 1H), 7.12-7.08 (m, 2H), 6.82-6.78 (m, 2H), 3.76 (s, 3H), 2.84 (s, 3H), 2.10 (d, *J* = 14.8 Hz, 1H), 1.91 (d, *J* = 14.8 Hz, 1H), 0.94 (d, *J* = 11.6 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.3, 159.0, 151.5, 133.2, 131.5, 127.7, 127.3, 123.0, 122.1, 113.9, 83.2, 68.0, 55.2, 24.8, 24.7, 24.48, 24.45. HRMS *m*/*z* (ESI+): Calculated for C₂₃H₂₉BNO₄⁺ ([M+H]⁺): 394.2184, found 394.2178.


(*R*)-2-Methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3-(p-tolyl)isoindolin-1-one (20):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 122-124 °C; 68% yield; $[\alpha]_D^{20} = -69.60$ (*c* 0.5, CH₂Cl₂), 93% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 90/10, 0.7 mL/min, 254 nm; t_{minor} = 9.16 min, t_{major} = 12.78 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.82 (d, *J* = 7.6 Hz, 1H), 7.42-7.34 (m, 2H), 7.19-7.17 (m, 1H), 7.10-7.05 (m, 4H), 2.84 (s, 3H), 2.28 (s, 3H), 2.12 (d, *J* = 14.8 Hz, 1H), 1.90 (d, *J* = 14.4 Hz, 1H), 0.93 (d, *J* = 12.0 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃): δ 168.4, 151.3, 138.2, 137.3, 131.5, 131.4, 129.3, 127.7, 125.8, 123.0, 122.1, 83.1, 68.2, 24.8, 24.43, 24.40, 20.9. HRMS *m/z* (ESI+): Calculated for C₂₃H₂₉BNO₃⁺ ([M+H]⁺): 378.2235, found 378.2233.



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	9.222	VB R	0.3217	725.10083	29.97994	50.7262
2	12.476	MM	0.5097	704.33844	23.03065	49.2738



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	9.157	VB	0.2631	297.92181	16.01150	3.6891
2	12.769	BB	0.4399	7777.83936	252.15144	96.3109

(*R*)-3-(4-Ethylphenyl)-2-methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2p):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow oil; 69% yield; $[\alpha]_D^{20} = -79.20$ (*c* 0.5, CH₂Cl₂), 96% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; t_{minor} = 13.11 min, t_{major} = 17.56 min]; ¹H NMR (500 MHz, CDCl₃): δ 7.83-7.81 (m, 1H), 7.42-7.35 (m, 2H), 7.21-7.19 (m, 1H), 7.12-7.08 (m, 4H), 2.85 (s, 3H), 2.59 (q, *J* = 7.5 Hz, 2H), 2.13 (d, *J* = 14.5 Hz, 1H), 1.91 (d, *J* = 14.5 Hz, 1H), 1.19 (t, *J* = 7.5 Hz, 3H), 0.94 (d, *J* = 15.0 Hz, 12H). ¹³C NMR (125 MHz, CDCl₃): δ 168.4, 151.4, 143.6, 138.6, 131.54, 131.50, 128.1, 127.7, 125.9, 123.0, 122.2, 83.2, 68.3, 28.2, 24.9, 24.48, 24.45, 15.2. HRMS *m*/*z* (ESI+): Calculated for C₂₄H₃₁BNO₃⁺ ([M+H]⁺): 392.2392, found 392.2390.



Signal 1: DAD1 A, Sig=254,4 Ref=360,100

ak RetTime ± [min]	Туре	Width [min]	Area [mAll*s]	Height [mAll]	Area %
			[IIIAO 3]	[IIIA0]	/0
1 13.763	BB	0.5526	3525.19458	92.50563	51.5186
2 18.070	BB	0.5376	3317.36646	90.09976	48.4814
		110		17,560	
10	12		4 16	18	20 mir
gnal 1: DA	D1 A,	Sig=254,	4 Ref=360,1	100	
ak RetTime ‡ [min] 	Туре	Width [min] 	Area [mAU*s]	Height [mAU]	Area %
	ak RetTime # [min] 1 13.763 2 18.070 3 2 18.070 gnal 1: DA ak RetTime # [min] 	ak RetTime Type # [min] 1 13.763 BB 2 18.070 BB gnal 1: DAD1 A, ak RetTime Type # [min] 	ak RetTime Type Width # [min] [min] 1 13.763 BB 0.5526 2 18.070 BB 0.5376 2 18.070 BB 0.5376 gnal 1: DAD1 A, Sig=254, ak RetTime Type Width # [min] [min]	ak RetTime Type Width Area # [min] [min] [mAU*s] 1 13.763 BB 0.5526 3525.19458 2 18.070 BB 0.5376 3317.36646 gnal 1: DAD1 A, Sig=254,4 Ref=360,1 ak RetTime Type Width Area # [min] [min] [min] [mAU*s]	ak RetTime Type Width Area Height # [min] [mAU*s] [mAU]

(R)-	3-(4-	-Fluorophenyl)-2-n	nethyl-3-((4,4,5,5-tetramethy	vl-1,3,2-dioxaboi	rolan-2-yl)m-
	2	17.560 BBA	0.6096 2.38947e4	562.51538	97.8587

522.85785

15.20172

2.1413

0.4993

ethyl)isoindolin-1-one (2q):

13.110 BB

1



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 118-120 °C; 57% yield; $[α]_D^{20} = -64.85$ (*c* 0.5, CH₂Cl₂), 95% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 230 nm; t_{minor} = 16.68 min, t_{major} = 18.78 min]; ¹H NMR (500 MHz, CDCl₃): δ 7.84-7.82 (m, 1H), 7.45-7.38 (m, 2H), 7.19-7.14 (m, 3H), 6.98-6.94 (m, 2H), 2.84 (s, 3H), 2.10 (d, *J* = 15.0 Hz, 1H), 1.90 (d, *J* = 14.5 Hz, 1H), 0.94 (d, *J* = 13.5 Hz, 12H). ¹³C NMR (125 MHz, CDCl₃): δ 168.3, 162.1 (d, *J* = 245.0 Hz), 151.1, 137.2 (d, *J* = 2.5 Hz), 131.7, 131.5, 127.94 (d, *J* = 7.5 Hz), 127.85, 123.2, 122.1, 115.5 (d, *J* = 21.25 Hz), 83.3, 67.9, 24.7, 24.48, 24.45. ¹⁹F NMR (377 MHz, CDCl₃): δ -114.8. HRMS *m*/*z* (ESI+): Calculated for C₂₂H₂₆BFNO₃⁺ ([M+H]⁺): 382.1984, found 382.1983.



Signal 4: DAD1 D, Sig=230,4 Ref=360,100



S39

Signal 4: DAD1 D, Sig=230,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	16.677	BB	0.4187	294.68369	10.15141	2.6923
2	18.779	BB	0.6198	1.06509e4	247.60484	97.3077

(*R*)-3-(3-Methoxyphenyl)-2-methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2r):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:3 (v/v); white solid; Mp = 130-132 °C; 77% yield; $[\alpha]_D^{20} = -90.90$ (*c* 0.25, CH₂Cl₂), 92% ee [Phenomenex Lux 5u Cellulose-1 column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 90/10, 0.7 mL/min, 260 nm; t_{minor} = 9.27 min, t_{major} = 11.29 min]; ¹H NMR (500 MHz, CDCl₃): δ 7.83-7.82 (m, 1H), 7.44-7.36 (m, 2H), 7.22-7.19 (m, 2H), 6.80-6.73 (m, 3H), 3.73 (s, 3H), 2.87 (s, 3H), 2.12 (d, *J* = 14.5 Hz, 1H), 1.91 (d, *J* = 14.5 Hz, 1H), 0.94 (d, *J* = 15.0 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.5, 159.9, 151.1, 143.2, 131.6, 131.5, 129.7, 127.8, 123.1, 122.1, 118.3, 112.5, 112.3, 83.2, 68.4, 55.2, 25.0, 24.49, 24.46. HRMS *m*/*z* (ESI+): Calculated for C₂₃H₂₉BNO₄⁺ ([M+H]⁺): 394.2184, found 394.2184.



Signal 5: DAD1 E, Sig=260,4 Ref=360,100



Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	9.269	BB	0.2175	223.21727	15.93195	4.1634
2	11.286	BB	0.2693	5138.22656	294.83466	95.8366

(*R*)-2-Methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3-(m-tolyl)isoindolin-1-one (2s):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 120-122 °C; 77% yield; $[\alpha]_D^{20} = -100.10 (c 0.5, CH_2Cl_2)$, 93% ee [Phenomenex Lux 5u Cellulose-1 column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 260 nm; t_{minor} = 10.81 min, t_{major} = 12.17 min]; ¹H NMR (500 MHz, CDCl₃): δ 7.84-7.82 (m, 1H), 7.43-7.36 (m, 2H), 7.21-7.17 (m, 2H), 7.06-7.04 (m, 2H), 6.94-6.93 (m, 1H), 2.86 (s, 3H), 2.26 (s, 3H), 2.14 (d, *J* = 14.5 Hz, 1H), 1.91 (d, *J* = 14.5 Hz, 1H), 0.94 (d, *J* = 15.0 Hz, 12H). ¹³C NMR (150

MHz, CDCl₃): δ 168.5, 151.3, 141.3, 138.4, 131.54, 131.49, 128.6, 128.4, 127.7, 126.5, 123.1, 123.0, 122.2, 83.2, 68.4, 24.9, 24.48, 24.45, 21.5. HRMS *m/z* (ESI+): Calculated for C₂₃H₂₉BNO₃⁺ ([M+H]⁺): 378.2235, found 378.2234.



Signal 5: DAD1 E, Sig=260,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	10.921	BB	0.2700	834.54108	47.73183	50.3805
2	12.396	BB	0.2983	821.93396	42.74848	49.6195
mAU 350					.172	
300					12	
200						N
150						\backslash
100				.813		\mathbf{A}
0				5		
9	9.5	10	10.5	11 11	1.5 12	12.5 min

Signal 5: DAD1 E, Sig=260,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	10.813	BB	0.2629	193.31874	11.22603	3.4936
2	12.172	BB	0.2839	5340.16895	288.61429	96.5064

(*R*)-3-(3,5-diMethylphenyl)-2-methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)m-ethyl)isoindolin-1-one (2t):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 120-121 °C; 71% yield; $[\alpha]_D^{22} = -83.75$ (*c* 0.5, CH₂Cl₂), 90% ee [Phenomenex Lux 5u Cellulose-2 column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 97/03, 0.7 mL/min, 230 nm; t_{major} = 24.73 min, t_{minor} = 27.41 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.83-7.81 (m, 1H), 7.43-7.34 (m, 2H), 7.21-7.19 (m, 1H), 6.85-6.79 (m, 3H), 2.85 (s, 3H), 2.22 (s, 6H), 2.13 (d, *J* = 14.8 Hz, 1H), 1.88 (d, *J* = 14.8 Hz, 1H), 0.93 (d, *J* = 11.2 Hz, 12H). ¹³C NMR (125 MHz, CDCl₃): δ 168.6, 151.4, 141.2, 138.2, 131.50, 131.48, 129.3, 127.7, 123.7, 123.0, 122.1, 83.1, 68.4, 24.9, 24.5, 24.4, 21.4. HRMS *m*/*z* (ESI+): Calculated for C₂₄H₃₁BNO₃⁺ ([M+H]⁺): 392.2392, found 392.2389.



Signal 4: DAD1 D, Sig=230,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	24.921	BV	0.6249	1.26691e5	2411.50269	48.9256
2	27.680	VB	0.6836	1.32256e5	2304.31201	51.0744



Signal 4: DAD1 D, Sig=230,4 Ref=360,100

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	24.732	BB	0.7185	1.07554e4	229.61444	94.9796
2	27.408	BB	0.5758	568.50330	11.72195	5.0204

(*R*)-3-(*Benzo*[*d*][1,3]*dioxo*l-5-yl)-2-*methy*l-3-((4,4,5,5-*tetramethy*l-1,3,2-*dioxaboro*la*n*-2-yl)*methy*l)*isoindo*lin-1-*one* (2*u*):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:3 (v/v); white solid; Mp = 55-57 °C; 42% yield; $[\alpha]_D^{22} = -59.65$ (*c* 0.5, CH₂Cl₂), 94% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 90/10, 0.7 mL/min, 254 nm; t_{minor} = 15.22 min, t_{major} = 18.24 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.83-7.80 (m, 1H), 7.44-7.36 (m, 2H), 7.20-7.18 (m, 1H), 6.79-6.71 (m, 2H), 6.51 (d, *J* = 1.6 Hz, 1H), 5.90 (dd, *J* = 10.0 Hz, 1.6 Hz, 2H), 2.84 (s, 3H), 2.05 (d, *J* = 14.8 Hz, 1H), 1.87 (d, *J* = 14.4 Hz, 1H), 0.93 (d, *J* = 12.0 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.3, 151.3, 148.1, 147.1, 135.4, 131.6, 131.5, 127.8, 123.1, 122.1, 119.5, 108.0, 106.7, 101.2, 83.2, 68.2, 24.8, 24.48, 24.46. HRMS *m/z* (ESI+): Calculated for C₂₃H₂₇BNO₅⁺ ([M+H]⁺): 408.1977, found 408.1974.





Signal 1: DAD1 A, Sig=254,4 Ref=360,100

(*R*)-2-Methyl-3-(naphthalen-2-yl)-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)isoindolin-1-one (2v):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); white solid; Mp = 168-170 °C; 64% yield; $[\alpha]_D^{20} = -$

105.25 (*c* 0.5, CH₂Cl₂), 84% ee [Daicel Chiralcel OD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; t_{minor} = 13.64 min, t_{major} = 15.86 min]; ¹H NMR (600 MHz, CDCl₃): δ 7.93-7.92 (m, 1H), 7.90-7.87 (m, 1H), 7.84-7.83 (m, 1H), 7.77-7.76 (m, 1H), 7.68-7.67 (m, 1H), 7.51-7.45 (m, 2H), 7.43-7.39 (m, 2H), 7.23-7.20 (m, 1H), 6.99-6.97 (m, 1H), 2.88 (s, 3H), 2.28 (d, *J* = 14.4 Hz, 1H), 2.07 (d, *J* = 14.4 Hz, 1H), 0.97 (d, *J* = 15.6 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.5, 151.0, 138.8, 133.1, 132.6, 131.7, 131.6, 128.6, 128.1, 127.9, 127.4, 126.4, 126.3, 125.2, 124.0, 123.1, 122.3, 83.2, 68.4, 24.9, 24.50, 24.46. HRMS *m*/*z* (ESI+): Calculated for C₂₆H₂₉BNO₃⁺ ([M+H]⁺): 414.2235, found 414.2228.





Signal 1: DAD1 A, Sig=254,4 Ref=360,100

```
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
```

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	13.638	BB	0.4175	1675.26428	59.67692	7.9616
2	15.855	MM	0.4739	1.93667e4	681.09363	92.0384

(*R*)-2-Methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3-(thiophen-3-yl)-isoindolin-1-one (2w):



Purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:5 (v/v); yellow oil; 65% yield; $[\alpha]_D^{20} = -62.90$ (*c* 0.25, CH₂Cl₂), 97% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 230 nm; t_{minor} = 21.02 min, t_{major} = 22.85 min]; ¹H NMR (600 MHz, CDCl₃): 7.83 (d, *J* = 7.8 Hz, 1H), 7.47-7.39 (m, 2H), 7.28-7.26 (m, 2H), 7.20-7.18 (m, 1H), 6.55-6.54 (m, 1H), 2.89 (s, 3H), 2.09 (d, *J* = 15.0 Hz, 1H), 1.96 (d, *J* = 15.0 Hz, 1H), 0.94 (d, *J* = 9.6 Hz, 12H). ¹³C NMR (150 MHz, CDCl₃): δ 168.0, 150.2, 143.8, 131.53, 131.52, 128.0, 126.5, 126.0, 123.1, 122.2, 122.0, 83.2, 66.3, 24.8, 24.5, 24.4. HRMS *m/z* (ESI+): Calculated for C₂₀H₂₅BNO₃S⁺([M+H]⁺): 370.1643, found 370.1643.





6. Scale-up experiment and synthetic transformations

6.1 Scale-up experiment



In an N₂-filled glovebox, to an oven-dried Schlenk tube equipped with a stir bar was charged with CuI (19 mg), (*R*)-xyl-BINAP (88 mg), and KO'Bu (168 mg). The tube was sealed with cap and removed from the glovebox. Toluene (10 mL) was then introduced via syringe. The mixture was stirred at 40 °C for 1 h. Then B₂pin₂ (381 mg) and **1a** (363 mg) were added into the mixture and warmed to 40 °C. The reaction was stirred at 40 °C for 15 h. When the reaction was completed, the mixture was extracted with EA. The combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel

eluenting with petroleum ether/EtOAc (5:1) to afford the products 2a with 81% yield and in 92% ee.

6.2 Synthetic transformations

Vulcanization of $2a^{[3]}$:



To a Schlenk tube equipped with a stirring bar was charged with **2a** (0.2 mmol, 1.0 equiv.), Lawesson's Reagent (0.2 mmol, 1.0 equiv.), and toluene (2.0 mL) under N₂ atmosphere. The reaction was stirred at 60 °C for 5 hours. When the reaction was completed, the mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with petroleum ether/ethyl acetate (v/v = 10:1) to afford the products **3**. Yellow solid; Mp = 138-140 °C; 64% yield; $[\alpha]_D^{27}$ = -161.25 (*c* 1.0, CH₂Cl₂), 93% ee [Daicel Chiralcel AD-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 95/05, 0.7 mL/min, 254 nm; t_{minor} = 8.02 min, t_{major} = 9.19 min]; ¹H NMR (500 MHz, CDCl₃): δ 8.07-8.05 (m, 1H), 7.46-7.40 (m, 2H), 7.32-7.26 (m, 3H), 7.20-7.18 (m, 1H), 7.14-7.11 (m, 2H), 3.23 (s, 3H), 2.19 (d, *J* = 14.5 Hz, 1H), 2.00 (d, *J* = 14.5 Hz, 1H), 0.94 (d, *J* = 22.0 Hz, 12H). ¹³C NMR (125 MHz, CDCl₃): δ 192.7, 149.7, 139.9, 138.0, 131.6, 128.9, 128.2, 128.1, 125.8, 125.2, 121.6, 83.4, 76.5, 30.4, 24.50, 24.49. HRMS *m*/*z* (ESI+): Calculated for C₂₂H₂₇BNO₂S⁺ ([M+H]⁺): 380.1850, found 380.1847.





```
Signal 1: VWD1 A, Wavelength=254 nm
```

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	8.016	BV	0.2504	519.91479	30.12285	3.4421
2	9.187	VV R	0.2814	1.45847e4	750.55206	96.5579

Oxidation of $2a^{[4]}$:



To a Schlenk tube equipped with a stirring bar was charged with **2a** (0.2 mmol, 1.0 equiv.), THF (2.0 mL), and H₂O (2.0 mL). Then NaBO₃•4H₂O (0.8 mmol, 4.0 equiv.) was added and stirred at room temperature for 4 hours. When the reaction was completed, the mixture was quenched with water and extracted with EA (3 times). The combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate/petroleum ether (v/v = 1:1) to afford the products **4**. White solid; Mp = 154-155 °C; 85% yield; $[\alpha]_D^{26} = -68.35$ (*c* 0.5, CH₂Cl₂), 95% ee [Daicel Chiralcel OJ-H column (25 cm × 0.46 cm ID), *n*-hexane/*i*-PrOH = 80/20, 0.7 mL/min, 254 nm; t_{major} = 8.56 min, t_{minor} = 11.56 min]; ¹H NMR (400 MHz, CDCl₃): δ 7.55 (d, *J* = 7.6 Hz, 1H), 7.36 (t, *J* = 7.2 Hz, 1H), 7.28-7.19 (m, 4H), 7.16 (d, *J* = 7.6 Hz, 1H), 7.08-7.06 (m, 2H), 4.47 (d, *J* = 12.0 Hz, 1H), 4.34 (d, *J* = 11.6 Hz, 1H), 3.43 (s, 1H), 2.54 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.5, 148.1, 137.4, 131.8, 131.7, 129.1, 128.3, 128.2, 126.1, 123.5, 122.0, 71.6, 63.3, 25.4. HRMS *m/z* (ESI+): Calculated for C₁₆H₁₆NO₂⁺ ([M+H]⁺): 254.1176, found 254.1172.



Peak RetTime Type Width Height Area Area % [min] [mAU*s] # [min] [mAU] ----| 1 9.180 BV R 0.1963 1388.86145 107.19008 50.8508 2 12.425 BB 0.2911 1342.38879 71.49325 49.1492 386^{3.10} mAU 3.557 300 250 200 150 100 11.559 50 0 10 14

Signal 1: VWD1 A, Wavelength=254 nm

Signal 1: VWD1 A, Wavelength=254 nm

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	8.557	MM	0.1905	3863.77563	337.96280	97.5333
2	11.559	VB R	0.2621	97.71657	5.75452	2.4667

Vinylation of **2a**^[5]:



To an oven-dried Schlenk tube equipped with a stirring bar was charged with **2a** and THF (2.0 mL) under N₂ atmosphere. The reaction was stirred at room temperature and vinylmagnesium bromide (0.8 mmol, 1 M in THF, 4.0 equiv.) was added slowly. After 30 min, the reaction was cooled to -78 °C and I₂ (0.8 mmol, 4.0 equiv.) dissolved in methanol (2.0 mL) was added into the mixture. When stirring at -78 °C for 30 min, NaOMe (0.32 mmol, 1.6 equiv.) dissolved in methanol (2.0 mL) was warmed to room temperature and stirred for 2 hours. When the reaction was completed, the mixture was quenched with saturated Na₂S₂O₃ aqueous solution and extracted with Et₂O (3 times). The combined organic phases were dried

over anhydrous Na₂SO₄ and concentrated reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with ethyl acetate/petroleum ether (v/v = 1:5) to afford the products **5**. White solid; Mp = 176-179 °C; 69% yield; $[\alpha]_D^{27}$ = -172.05 (*c* 0.5, CH₂Cl₂), 94% ee [Daicel Chiralcel AS-H column (25 cm × 0.46 cm ID), *n*hexane/*i*-PrOH = 90/10, 0.7 mL/min, 254 nm; t_{major} = 14.29 min, t_{minor} = 18.28 min]; ¹H NMR (500 MHz, CDCl₃): δ 7.87-7.86 (m, 1H), 7.47-7.39 (m, 2H), 7.35-7.27 (m, 3H), 7.20-7.15 (m, 3H), 5.15-5.07 (m, 1H), 5.03 (dd, *J* = 17.5 Hz, 2.5 Hz, 1H), 4.92 (dd, *J* = 10.0 Hz, 2.0 Hz, 1H), 3.32 (dd, *J* = 14.0 Hz, 5.5 Hz, 1H), 3.12 (dd, *J* = 14.0 Hz, 7.5 Hz, 1H), 2.84 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 168.7, 149.5, 139.7, 131.8, 131.6, 130.8, 128.9, 128.1, 128.0, 126.1, 123.4, 121.9, 119.5, 69.8, 38.2, 25.0. HRMS *m*/*z* (ESI+): Calculated for C₁₈H₁₈NO⁺ ([M+H]⁺): 264.1383, found 264.1380.





Signal 1: VWD1 A, Wavelength=254 nm

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	14.293	BB	0.5689	1.38762e4	368.03012	97.1333
2	18.276	BB	0.6002	409.53098	9.64785	2.8667

7. Crystal report

The single crystalsof **4** (CCDC 2350769) was grown in ethyl acetate by slow evaporation method. A suitable crystal (0.01mm*0.02mm*0.03mm) was selected and mounted on a Bruker D8 Venture diffractometer with MoK α radiation ($\lambda = 0.71073$ Å) (or CuK α radiation ($\lambda = 1.54178$ Å) or CaK α radiation ($\lambda = 1.34139$ Å) for cell determination and subsequent data collection at 169 K. Using Olex2, the structure was solved with the ShelXT structure solution program using Intrinsic Phasing and refined with the ShelXL refinement package using Least Squares minimisation. See below for other details.

Crystal report of compounds 4 :



Figure S1. Ortep drawing of compound 4 with 50% ellipsoids

Datablock: cu_220705_xjq_0m

Bond precision:	C-C = 0.0033 A	Wavelength	Wavelength=1.54178		
Cell:	a=9.2774(3) alpha=90	b=11.2639(4) beta=90	c=12.0479(4) gamma=90		
Temperature:	169 K		2		
	Calculated	Reported			
Volume	1259.00(7)	1259.00(7)		
Space group	P 21 21 21	P 21 21 2	21		
Hall group	P 2ac 2ab	P 2ac 2al	o		
Moiety formula	C16 H15 N O2	C16 H15 M	N 02		
Sum formula	C16 H15 N O2	C16 H15 M	N 02		
Mr	253.29	253.29			
Dx,g cm-3	1.336	1.336			
Z	4	4			
Mu (mm-1)	0.708	0.708			
F000	536.0	536.0			
F000'	537.60				
h,k,lmax	11,13,14	11,13,14			
Nref	2307[1345]	2293			
Tmin,Tmax	0.747,0.781	0.567,0.7	753		
Tmin'	0.678				
Correction metho AbsCorr = MULTI-	od= # Reported T Li -SCAN	imits: Tmin=0.567 Tr	max=0.753		
Data completenes	ss= 1.70/0.99	Theta(max) = 68.31	15		
R(reflections)=	0.0491(2282)		wR2(reflections)= 0.1199(2293)		
S = 1.256	Npar= 1	74	0.1199 (2290)		

The following ALERTS were generated. Each ALERT has the format test-name_ALERT_alert-type_alert-level. Click on the hyperlinks for more details of the test.		
Alert level C PLAT911_ALERT_3_C Missing FCF Refl Between Thmin & STh/L= 0.600 PLAT913_ALERT_3_C Missing # of Very Strong Reflections in FCF	6 4	Report Note
Alert level G PLAT007_ALERT_5_G Number of Unrefined Donor-H Atoms PLAT791_ALERT_4_G Model has Chirality at C8 (Sohnke SpGr) PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L= 0.600 PLAT933_ALERT_2_G Number of HKL-OMIT Records in Embedded .res File PLAT961_ALERT_5_G Dataset Contains no Negative Intensities PLAT978_ALERT_2_G Number C-C Bonds with Positive Residual Density.	1 R 2 4 Please 0	Report Verify Note Note Check Info
<pre>0 ALERT level A = Most likely a serious problem - resolve or expla 0 ALERT level B = A potentially serious problem, consider careful: 2 ALERT level C = Check. Ensure it is not caused by an omission of 6 ALERT level G = General information/check it is not something un 0 ALERT type 1 CIF construction/syntax error, inconsistent or miss 2 ALERT type 2 Indicator that the structure model may be wrong or 2 ALERT type 3 Indicator that the structure quality may be low 2 ALERT type 4 Improvement, methodology, query or suggestion 2 ALERT type 5 Informative message, check</pre>	ain ly r oversigh nexpected sing data deficient	at :

It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more serious problems it may be necessary to carry out additional measurements or structure refinements. However, the purpose of your study may justify the reported deviations and the more serious of these should normally be commented upon in the discussion or experimental section of a paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify outliers and unusual parameters, but every test has its limitations and alerts that are not important in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no aspects of the results needing attention. It is up to the individual to critically assess their own results and, if necessary, seek expert advice.

Publication of your CIF in IUCr journals

A basic structural check has been run on your CIF. These basic checks will be run on all CIFs submitted for publication in IUCr journals (*Acta Crystallographica, Journal of Applied Crystallography, Journal of Synchrotron Radiation*); however, if you intend to submit to *Acta Crystallographica Section C* or *E* or *IUCrData*, you should make sure that full publication checks are run on the final version of your CIF prior to submission.

Publication of your CIF in other journals

Please refer to the *Notes for Authors* of the relevant journal for any special instructions relating to CIF submission.

PLATON version of 18/05/2022; check.def file version of 17/05/2022

8. References

[1] Dehury, S. K. X-Ray Crystal Structure and Photo Chemistry of *N*-Methyl-*N*-(1-phenylvinyl)benzamide. *J. Chem. Crystallogr.* **2011**, *41*, 1386-1390.

[2] Tait, M.; Donnard, M.; Minassi, A.; Lefranc, J.; Bechi, B.; Carbone, G.; O'Brien, P.; Clayden, J. Amines Bearing Tertiary Substituents by Tandem Enantioselective Carbolithiation-Rearrangement of Vinylureas. *Org. Lett.* **2013**, *15*, 34-37.

[3] Huang, W.; Shrestha, M.; Wang, C.; Fang, K.; Teng, Y.; Qu, J.; Chen, Y. Asymmetric Synthesis of 3-Benzyl and Allyl Isoindolinones by Pd-Catalyzed Dicarbofunctionalization of 1,1-Disubstituted Enamides. *Org. Chem. Front.* **2021**, *8*, 4106-4111.

[4] Whyte, A.; Torelli, A.; Mirabi, B.; Lautens, M. Enantioselective Copper-Catalyzed Borylative Cyclization with Cyclic Imides. *Org. Lett.* **2019**, *21*, 8373-8377.

[5] Sonawane, R. P.; Rabalakos, V. J. C.; Gauthier, R. L.; Scott, H. K.; Aggarwal, V. K.
Enantioselective Construction of Quaternary Stereogenic Centers from Tertiary Boronic
Esters: Methodology and Applications. *Angew. Chem. Int. Ed.* 2011, *50*, 3760-3763.

9. Copies of NMR spectra



Figure S2. ¹H NMR spectrum of compound **1a** (600 MHz, CDCl₃)



Figure S3. ¹³C NMR spectrum of compound 1a (150 MHz, CDCl₃)



Figure S4. ¹H NMR spectrum of compound 1a' (400 MHz, CDCl₃)



Figure S5. ¹³C NMR spectrum of compound 1a' (100 MHz, CDCl₃)



Figure S6. ¹H NMR spectrum of compound 1b (600 MHz, CDCl₃)



Figure S7. ¹³C NMR spectrum of compound 1b (150 MHz, CDCl₃)



Figure S8. ¹H NMR spectrum of compound 1c (600 MHz, CDCl₃)



Figure S9. ¹³C NMR spectrum of compound 1c (150 MHz, CDCl₃)



Figure S10. ¹H NMR spectrum of compound 1d (600 MHz, CDCl₃)



Figure S11. ¹³C NMR spectrum of compound 1d (150 MHz, CDCl₃)



Figure S12. ¹H NMR spectrum of compound 1e (600 MHz, CDCl₃)



Figure S13. ¹³C NMR spectrum of compound 1e (150 MHz, CDCl₃)



Figure S14. ¹⁹F NMR spectrum of compound 1e (377 MHz, CDCl₃)



Figure S15. ¹H NMR spectrum of compound 1f (600 MHz, CDCl₃)


Figure S16. ¹³C NMR spectrum of compound 1f (150 MHz, CDCl₃)



 $< -62.90 \\ < -63.02$

Figure S17. ¹⁹F NMR spectrum of compound **1f** (377 MHz, CDCl₃)



Figure S18. ¹H NMR spectrum of compound 1g (600 MHz, CDCl₃)



Figure S19. ¹³C NMR spectrum of compound 1g (150 MHz, CDCl₃)



Figure S20. ¹H NMR spectrum of compound 1h (600 MHz, CDCl₃)



Figure S21. ¹³C NMR spectrum of compound 1h (150 MHz, CDCl₃)



Figure S22. ¹H NMR spectrum of compound 1i (600 MHz, CDCl₃)



Figure S23. ¹³C NMR spectrum of compound 1i (150 MHz, CDCl₃)



Figure S24. ¹H NMR spectrum of compound 1j (600 MHz, CDCl₃)



Figure S25. ¹³C NMR spectrum of compound 1j (150 MHz, CDCl₃)



Figure S26. ¹H NMR spectrum of compound 1k (600 MHz, CDCl₃)



Figure S27. ¹³C NMR spectrum of compound 1k (150 MHz, CDCl₃)



Figure S28. ¹⁹F NMR spectrum of compound 1k (377 MHz, CDCl₃)



Figure S29. ¹H NMR spectrum of compound 11 (500 MHz, CDCl₃)



Figure S30. ¹³C NMR spectrum of compound 11 (150 MHz, CDCl₃)



Figure S31. ¹H NMR spectrum of compound 1m (600 MHz, CDCl₃)



Figure S32. ¹³C NMR spectrum of compound 1m (150 MHz, CDCl₃)



Figure S33. ¹⁹H NMR spectrum of compound 1m (377 MHz, CDCl₃)



Figure S34. ¹H NMR spectrum of compound 1n (600 MHz, CDCl₃)



Figure S35. ¹³C NMR spectrum of compound 1n (150 MHz, CDCl₃)



Figure S36. ¹H NMR spectrum of compound 10 (600 MHz, CDCl₃)



Figure S37. ¹³C NMR spectrum of compound **10** (150 MHz, CDCl₃)



Figure S38. ¹H NMR spectrum of compound 1p (600 MHz, CDCl₃)



Figure S39. ¹³C NMR spectrum of compound 1p (150 MHz, CDCl₃)



Figure S340. ¹H NMR spectrum of compound 1q (600 MHz, CDCl₃)



Figure S41. ¹³C NMR spectrum of compound 1q (150 MHz, CDCl₃)



Figure S42. ¹⁹F NMR spectrum of compound 1q (377 MHz, CDCl₃)



Figure S43. ¹H NMR spectrum of compound 1r (600 MHz, CDCl₃)



Figure S44. ¹³C NMR spectrum of compound 1r (150 MHz, CDCl₃)



Figure S45. ¹H NMR spectrum of compound 1s (600 MHz, CDCl₃)



Figure S46. ¹³C NMR spectrum of compound 1s (150 MHz, CDCl₃)



Figure S47. ¹H NMR spectrum of compound 1t (600 MHz, CDCl₃)



Figure S48. ¹³C NMR spectrum of compound 1t (150 MHz, CDCl₃)



Figure S49. ¹H NMR spectrum of compound 1u (600 MHz, CDCl₃)



Figure S50. ¹³C NMR spectrum of compound 1u (150 MHz, CDCl₃)



057 041

842

830 827

Figure S51. ¹H NMR spectrum of compound **1v** (600 MHz, CDCl₃)


Figure S52. ¹³C NMR spectrum of compound 1v (150 MHz, CDCl₃)



Figure S53. ¹H NMR spectrum of compound 1w (600 MHz, CDCl₃)



Figure S54. ¹³C NMR spectrum of compound **1w** (150 MHz, CDCl₃)



Figure S55. ¹H NMR spectrum of compound 1x (500 MHz, CDCl₃)



Figure S56. ¹³C NMR spectrum of compound 1x (125 MHz, CDCl₃)



Figure S57. ¹H NMR spectrum of compound 1y (500 MHz, CDCl₃)



Figure S58. ¹³C NMR spectrum of compound 1y (125 MHz, CDCl₃)



Figure S59. ¹H NMR spectrum of compound 1z (500 MHz, CDCl₃)



Figure S60. ¹³C NMR spectrum of compound 1z (125 MHz, CDCl₃)



Figure S61. ¹H NMR spectrum of compound 2a (600 MHz, CDCl₃)



Figure S62. ¹³C NMR spectrum of compound 2a (150 MHz, CDCl₃)



Figure S63. ¹H NMR spectrum of compound 2b (400 MHz, CDCl₃)



Figure S64. ¹³C NMR spectrum of compound 2b (150 MHz, CDCl₃)



Figure S65. ¹H NMR spectrum of compound 2c (600 MHz, CDCl₃)



Figure S66. ¹³C NMR spectrum of compound 2c (150 MHz, CDCl₃)



Figure S67. ¹H NMR spectrum of compound 2d (600 MHz, CDCl₃)



Figure S68. ¹³C NMR spectrum of compound 2d (100 MHz, CDCl₃)



Figure S69. ¹H NMR spectrum of compound 2e (600 MHz, CDCl₃)



Figure S70. ¹³C NMR spectrum of compound 2e (150 MHz, CDCl₃)



Figure S71. ¹⁹F NMR spectrum of compound 2e (377 MHz, CDCl₃)



Figure S72. ¹H NMR spectrum of compound 2f (600 MHz, CDCl₃)



Figure S73. ¹³C NMR spectrum of compound 2f (150 MHz, CDCl₃)



Figure S74. ¹⁹F NMR spectrum of compound **2f** (377 MHz, CDCl₃)



Figure S75. ¹H NMR spectrum of compound 2g (600 MHz, CDCl₃)



Figure S76. ¹³C NMR spectrum of compound 2g (150 MHz, CDCl₃)



Figure S77. ¹H NMR spectrum of compound **2h** (400 MHz, CDCl₃)



Figure S78. ¹³C NMR spectrum of compound 2h (150 MHz, CDCl₃)



Figure S79. ¹H NMR spectrum of compound 2i (600 MHz, CDCl₃)



Figure S80. ¹³C NMR spectrum of compound 2i (150 MHz, CDCl₃)



Figure S81. ¹H NMR spectrum of compound 2j (600 MHz, CDCl₃)



Figure S82. ¹³C NMR spectrum of compound 2j (150 MHz, CDCl₃)



Figure S83. ¹H NMR spectrum of compound 2k (600 MHz, CDCl₃)



Figure S84. ¹³C NMR spectrum of compound 2k (150 MHz, CDCl₃)





Figure S86. ¹H NMR spectrum of compound 2l (600 MHz, CDCl₃)



Figure S87. ¹³C NMR spectrum of compound 2l (150 MHz, CDCl₃)


Figure S88. ¹H NMR spectrum of compound 2m (400 MHz, CDCl₃)



Figure S89. ¹³C NMR spectrum of compound 2m (125 MHz, CDCl₃)



0 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -125 -130 -135 -140 -145 -150 -155 -160 -165 -170 -175 -1 fl (ppm)

Figure S90. ¹⁹F NMR spectrum of compound 2m (377 MHz, CDCl₃)



Figure S91. ¹H NMR spectrum of compound 2n (400 MHz, CDCl₃)



Figure S92. ¹³C NMR spectrum of compound 2n (150 MHz, CDCl₃)



Figure S93. ¹H NMR spectrum of compound 20 (400 MHz, CDCl₃)



Figure S94. ¹³C NMR spectrum of compound 20 (100 MHz, CDCl₃)



Figure S95. ¹H NMR spectrum of compound **2p** (500 MHz, CDCl₃)



Figure S96. ¹³C NMR spectrum of compound 2p (125 MHz, CDCl₃)



Figure S97. ¹H NMR spectrum of compound 2q (500 MHz, CDCl₃)



Figure S98. ¹³C NMR spectrum of compound 2q (125 MHz, CDCl₃)



Figure S99. ¹⁹F NMR spectrum of compound 2q (377 MHz, CDCl₃)



Figure S100. ¹H NMR spectrum of compound 2r (500 MHz, CDCl₃)



Figure S101. ¹³C NMR spectrum of compound 2r (150 MHz, CDCl₃)



Figure S102. ¹H NMR spectrum of compound 2s (500 MHz, CDCl₃)



Figure S103. ¹³C NMR spectrum of compound 2s (150 MHz, CDCl₃)



Figure S104. ¹H NMR spectrum of compound 2t (400 MHz, CDCl₃)



Figure S105. ¹³C NMR spectrum of compound 2t (125 MHz, CDCl₃)



Figure S106. ¹H NMR spectrum of compound 2u (400 MHz, CDCl₃)



Figure S107. ¹³C NMR spectrum of compound 2u (150 MHz, CDCl₃)

)0



Figure S108. ¹H NMR spectrum of compound 2v (600 MHz, CDCl₃)



Figure S109. ¹³C NMR spectrum of compound 2v (150 MHz, CDCl₃)



Figure S110. ¹H NMR spectrum of compound **2w** (600 MHz, CDCl₃)



Figure S111. ¹³C NMR spectrum of compound **2w** (150 MHz, CDCl₃)



Figure S112. ¹H NMR spectrum of compound 3 (500 MHz, CDCl₃)



Figure S113. ¹³C NMR spectrum of compound 3 (125 MHz, CDCl₃)



Figure S114. ¹H NMR spectrum of compound 4 (400 MHz, CDCl₃)



Figure S115. ¹³C NMR spectrum of compound 4 (100 MHz, CDCl₃)



Figure S116. ¹H NMR spectrum of compound 5 (500 MHz, CDCl₃)



Figure S117. ¹³C NMR spectrum of compound 5 (125 MHz, CDCl₃)